Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
暂无分享,去创建一个
G. Rosner | M. Ratain | D. Hollis | M. Egorin | D. Rosen | Antonius A. Miller | S. Lichtman | R. Parise | E. Lester | C. Rhoades | S. Cullinan | F. Millard | J. Byrd | M. J. Egorin | D. M. Rosen | Stuart M. Lichtman | Antonius A. Miller | G L Rosner | Chris A. Rhoades | Eric P. Lester | Stephen A. Cullinan | Robert A. Parise
[1] E. Kohn,et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary , 2010, Cancer.
[2] P. Neuvonen,et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. , 2005, Basic & clinical pharmacology & toxicology.
[3] V. Zagonel,et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] R. Paridaens,et al. Taxanes in elderly breast cancer patients. , 2004, Cancer treatment reviews.
[5] A. Argiris,et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Rosner,et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] L. Siu,et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Perez,et al. Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer* , 2002, Breast Cancer Research and Treatment.
[9] J. Verweij,et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Fidias,et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] E. Perez,et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Fried,et al. Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.
[13] L. Repetto,et al. Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. , 2001, Critical reviews in oncology/hematology.
[14] G. Rosner,et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[16] G. Rosner,et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Yancik. Cancer burden in the aged , 1997, Cancer.
[18] O Pelkonen,et al. Age and cytochrome P450‐linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions , 1997, Clinical pharmacology and therapeutics.
[19] H. Choy,et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. , 1995, Journal of the National Cancer Institute.
[20] H. Rosing,et al. Limited Sampling Strategies for Investigating Paclitaxel Pharmacokinetics in Patients Receiving 175 mg/m2 as a 3-Hour Infusion , 1995 .
[21] W. Satariano,et al. The Effect of Comorbidity on 3-Year Survival of Women with Primary Breast Cancer , 1994, Annals of Internal Medicine.
[22] M. Egorin,et al. Cancer pharmacology in the elderly. , 1993, Seminars in oncology.
[23] N W Shock,et al. Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.
[24] C. Begg,et al. Clinical trials and drug toxicity in the elderly. The experience of the eastern cooperative oncology group , 1983, Cancer.
[25] Gary G. Koch,et al. Average Partial Association in Three-way Contingency Tables: a Review and Discussion of Alternative Tests , 1978 .
[26] E. Lehmann,et al. Nonparametrics: Statistical Methods Based on Ranks , 1976 .
[27] G. Forbes,et al. Adult lean body mass declines with age: some longitudinal observations. , 1970, Metabolism: clinical and experimental.
[28] I. Edelman,et al. Anatomy of body water and electrolytes. , 1959, The American journal of medicine.
[29] L. Repetto,et al. Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer , 2004, Drugs in R&D.
[30] E. Reed,et al. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer , 2004, Cancer Chemotherapy and Pharmacology.
[31] C. Seynaeve,et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. , 2003, European journal of cancer.
[32] G. Bonadonna,et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D. Lowenthal,et al. Geriatric pharmacology: basic and clinical considerations. , 1992, Annual review of pharmacology and toxicology.
[34] H. Toutenburg,et al. Lehmann, E. L., Nonparametrics: Statistical Methods Based on Ranks, San Francisco. Holden‐Day, Inc., 1975. 480 S., $ 22.95 . , 1977 .
[35] A. H. Norris,et al. Age differences in the water content of the body as related to basal oxygen consumption in males. , 1963, Journal of gerontology.